Pure Global
NCT06323356

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Adult Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Takeda·Phase 3·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Generalized Pustular Psoriasis,Erythrodermic Psoriasis
Drug/Device/Intervention
TAK-279
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Takeda
Location
Nagoya,Toyoake,Kisarazu,Urayasu,Kitakyushu,Isesaki,Kobe,Isehara,Tsu,Hirakata,Iruma,Chuo City,Itabashi-ku,Minato-ku,Shinjuku-ku,Fukuoka,Kyoto,Okayama,Osaka,Osaka, Japan
Timeline & enrollment
Phase
Phase 3
Start date
Mar 19, 2024
End date
Mar 27, 2026
Enrollment
20 participants
Primary outcome

Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) With a ≥2-Point Decrease from Baseline at Week 16,Percentage of Participants Achieving ≥75% Improvement from Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 16

Summary

The main aim of this study is to check if TAK-279 improves symptoms of With Generalized
 Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP) and side effect from the study
 treatment or TAK-279.
 
 All participants will be assigned to study treatments of TAK-279 and will be treated with
 TAK-279 if the participants meet the study rules.
 
 Participants will be in the study for up to 61 weeks including 52 weeks of study treatment.
 During the study, participants will visit their study clinic for multiple times.

ICD-10 classifications
Generalized pustular psoriasisPsoriasisOther psoriasisPsoriasis, unspecifiedArthropathic psoriasis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06323356
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06323356 through Pure Global AI's free database. This Phase 3 trial is sponsored by Takeda and is currently Recruiting. The study focuses on Generalized Pustular Psoriasis,Erythrodermic Psoriasis. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.